Risk Factors for Cardiovascular Disease in Rheumatoid Arthritis: Defining Treatment Thresholds

VINOD RAVINDRAN and RODNEY A. HUGHES

J Rheumatol 2010;37;200
http://www.jrheum.org/content/37/1/200

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Risk Factors for Cardiovascular Disease in Rheumatoid Arthritis: Defining Treatment Thresholds

To the Editor:

We read with interest the very insightful editorial by Dessein, et al1 on the determinants of dyslipidemia in rheumatoid arthritis (RA) in a recent issue of The Journal. There is little doubt that dyslipidemia participates in the atherogenesis of RA even when the disease is treated with disease-modifying antirheumatic drugs (DMARD), and its determinants comprise more of the conventional dyslipidemia risk factors than RA characteristics2. The question is how to best define the thresholds for conventional risk factors where interventions would be necessary.

Although cardiovascular disease (CVD) is highly prevalent in RA, identification is often difficult on clinical grounds alone, especially where reduced physical exertion and symptoms of CVD may be attributed to musculoskeletal rather than cardiac causes2. Further, it may be clinically silent in many patients, emphasizing the need for a high degree of awareness3. Close attention to the management of traditional cardiovascular risk factors is therefore essential in this group of patients4,5. Both rheumatologists and community physicians are therefore interested in knowing thresholds where treatment would be indicated for primary prevention of CVD in RA.

The modified Joint British Societies (JBS2) CVD risk calculator6 is a tool for estimating CVD risk (nonfatal myocardial infarction and stroke, coronary and stroke death, and new angina pectoris) for Caucasian individuals who have not already developed coronary heart disease or other major atherosclerotic disease based on age, sex, smoking habit, systolic blood pressure, and the ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol. This tool is an aid to making clinical decisions about how intensively to intervene on lifestyle and whether to use antihypertensive, lipid-lowering, and antiplatelet medication. A total CVD risk of >10% is defined as high risk and requires professional lifestyle intervention and, where appropriate, drug therapies to achieve the lifestyle and risk factor targets. It is recommended that such calculated risk be doubled7 to account for the excess risk associated with chronic inflammation in RA. We would like to share our experience in using this tool to assess the CVD risk in patients with RA.

Caucasian patients with RA were prospectively studied. All were assessed for age, sex, RA disease duration and activity and therapy, smoking status, body mass index, systolic blood pressure, fasting blood glucose, total and HDL cholesterol, family history of premature coronary heart disease or stroke, and preexisting cardiovascular comorbidity. Absolute 10-year CVD risk was calculated using the JBS2 CVD risk calculator6, which is used for nondiabetic populations in all age groups.

Sixty-five patients [46 women (71%); mean age 63 ± 11.95 yrs, mean disease duration 13.6 ± 9.75 yrs] were included. Thirty-seven (57%) patients had known cardiovascular comorbidities (hypertension 29, angina pectoris, myocardial infarction, cerebrovascular accident 2, peripheral vascular disease 3, hyperlipidemia 18, and diabetes 3). Table 1 gives details of individual risk factors in 28 (43%) patients who had no known cardiovascular comorbidity. Absolute 10-year CVD risk was calculated using the JBS2 CVD risk calculator6, which is used for nondiabetic populations in all age groups.

Table 1. Twenty-eight patients with rheumatoid arthritis without known cardiovascular comorbidity: demographic and disease characteristics and individual risk factors.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs (mean ± SD)</td>
<td>58.82 ± 13.11</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>22 (79)</td>
</tr>
<tr>
<td>Disease duration, yrs (mean ± SD)</td>
<td>10.67 ± 7.21</td>
</tr>
<tr>
<td>DAS28, mean ± SD</td>
<td>2.5 ± 0.7</td>
</tr>
<tr>
<td>TC/HDL cholesterol ratio, mmol/l (mean ± SD)</td>
<td>3.73 ± 0.83</td>
</tr>
<tr>
<td>Fasting glucose, mmol/l (mean ± SD)</td>
<td>4.69 ± 0.55</td>
</tr>
<tr>
<td>Body mass index, kg/m² (mean ± SD)</td>
<td>27.18 ± 5.11</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg (mean ± SD)</td>
<td>124.67 ± 13.59</td>
</tr>
<tr>
<td>Smokers, n (%)</td>
<td>9 (32)</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; CVD: cardiovascular disease. * Number of RA patients after CVD risk was multiplied by 2.

VINOD RAVINDRAN, MD, MRCP; RODNEY A. HUGHES, MD, FRCP, Department of Rheumatology, St. Peter’s Hospital, Guildford Road, Chertsey, KT16 0PZ, United Kingdom. Address correspondence to Dr. V. Ravindran; E-mail: drvinod12@gmail.com

REFERENCES


J Rheumatol 2010;37:1; doi:10.3899/jrheum.090758